Stanley Bridges, MD
Rheumatology · New York, NYNPI 1205876307
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,536 of the $3,679 with a category attached, or 96.1%. 4 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 55.9% of the total. Reporting peaked in 2020 at $2,181 and has fallen 99.2% since, to $18 in 2023.
Across 4 payments — averaging $919.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Pfizer$1K
- UCB, Inc.$125
- Lilly USA, LLC$18
Across 4 payments — averaging $82,944 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$332K
What the payments were for
- Speaking & faculty fees$3,53696%
- Food & beverage$1434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $2,056 |
| Pfizer | 1 | $1,480 |
| UCB, Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFLECTRA$1,480
How this compares
$3,679 in reported general payments places this provider in the 60th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 25 | $386,587 |
| EnbrelEtanercept | 22 | $208,410 |
| Xeljanz XrTofacitinib Citrate | 12 | $65,798 |
| MethotrexateMethotrexate Sodium | 36 | $1,475 |
| Prednisone | 16 | $91 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.